Posts tagged as

Michael Haller

Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes

UFDI investigators and collaborators found that granulocyte colony stimulating factor monotherapy did not affect C-peptide production, HbA1c, or insulin dose.This study supports the continued exploration of G-CSF and other mobilizing agents in subjects with T1D, but only when combined with immunodepleting agents where synergistic mechanisms of action have previously demonstrated…

Screening for T1D risk to reduce DKA is not economically viable

Several studies have documented reduced incidence of diabetic ketoacidosis (DKA) in new-onset T1D when high-risk children are identified at an early age. As a result, researchers have questioned whether T1D screening for the purpose of preventing DKA is a feasible option. UF researchers worked with Abt Associates to perform a…

New Onset T1D Study: Pancreatic Volume in Preclinical Type 1 Diabetes

UF researchers are seeking to determine differences in pancreatic volume between new-onset Type 1 Diabetes (T1D) patients, antibody positive subjects at increased risk for T1D, and healthy controls. The study will also be used to determine if pancreatic volume correlates with indirect biochemical markers of endocrine and exocrine pancreatic function.